326 related articles for article (PubMed ID: 34248942)
1. Efficacy and Safety of Bone Marrow-Derived Mesenchymal Stem Cells for Chronic Antibody-Mediated Rejection After Kidney Transplantation- A Single-Arm, Two-Dosing-Regimen, Phase I/II Study.
Wei Y; Chen X; Zhang H; Su Q; Peng Y; Fu Q; Li J; Gao Y; Li X; Yang S; Ye Q; Huang H; Deng R; Li G; Xu B; Wu C; Wang J; Zhang X; Su X; Liu L; Xiang AP; Wang C
Front Immunol; 2021; 12():662441. PubMed ID: 34248942
[TBL] [Abstract][Full Text] [Related]
2. Infusion of third-party mesenchymal stromal cells after kidney transplantation: a phase I-II, open-label, clinical study.
Erpicum P; Weekers L; Detry O; Bonvoisin C; Delbouille MH; Grégoire C; Baudoux E; Briquet A; Lechanteur C; Maggipinto G; Somja J; Pottel H; Baron F; Jouret F; Beguin Y
Kidney Int; 2019 Mar; 95(3):693-707. PubMed ID: 30528263
[TBL] [Abstract][Full Text] [Related]
3. Safety of allogeneic bone marrow derived mesenchymal stromal cell therapy in renal transplant recipients: the neptune study.
Reinders ME; Dreyer GJ; Bank JR; Roelofs H; Heidt S; Roelen DL; Zandvliet ML; Huurman VA; Fibbe WE; van Kooten C; Claas FH; Rabelink TJ; de Fijter JW
J Transl Med; 2015 Nov; 13():344. PubMed ID: 26537851
[TBL] [Abstract][Full Text] [Related]
4. Autologous bone marrow-derived mesenchymal stromal cells for the treatment of allograft rejection after renal transplantation: results of a phase I study.
Reinders ME; de Fijter JW; Roelofs H; Bajema IM; de Vries DK; Schaapherder AF; Claas FH; van Miert PP; Roelen DL; van Kooten C; Fibbe WE; Rabelink TJ
Stem Cells Transl Med; 2013 Feb; 2(2):107-11. PubMed ID: 23349326
[TBL] [Abstract][Full Text] [Related]
5. Marrow Mesenchymal Stem Cells Effectively Reduce Histologic Changes in a Rat Model of Chronic Renal Allograft Rejection.
Yu P; Wang Z; Liu Y; Xiao Z; Guo Y; Li M; Zhao M
Transplant Proc; 2017 Nov; 49(9):2194-2203. PubMed ID: 29149982
[TBL] [Abstract][Full Text] [Related]
6. Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial.
Tan J; Wu W; Xu X; Liao L; Zheng F; Messinger S; Sun X; Chen J; Yang S; Cai J; Gao X; Pileggi A; Ricordi C
JAMA; 2012 Mar; 307(11):1169-77. PubMed ID: 22436957
[TBL] [Abstract][Full Text] [Related]
7. Lentivirus-mediated IL-10-expressing Bone Marrow Mesenchymal Stem Cells promote corneal allograft survival
Lu X; Ru Y; Chu C; Lv Y; Gao Y; Jia Z; Huang Y; Zhang Y; Zhao S
Theranostics; 2020; 10(18):8446-8467. PubMed ID: 32724480
[No Abstract] [Full Text] [Related]
8. Mesenchymal Stromal Cell Therapy for Chronic Lung Allograft Dysfunction: Results of a First-in-Man Study.
Chambers DC; Enever D; Lawrence S; Sturm MJ; Herrmann R; Yerkovich S; Musk M; Hopkins PM
Stem Cells Transl Med; 2017 Apr; 6(4):1152-1157. PubMed ID: 28186707
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic mesenchymal stem cell as induction therapy to prevent both delayed graft function and acute rejection in deceased donor renal transplantation: study protocol for a randomized controlled trial.
Sun Q; Hong L; Huang Z; Na N; Hua X; Peng Y; Zhao M; Cao R; Sun Q
Trials; 2017 Nov; 18(1):545. PubMed ID: 29145879
[TBL] [Abstract][Full Text] [Related]
10. Mesenchymal stromal cells in renal transplantation: opportunities and challenges.
Casiraghi F; Perico N; Cortinovis M; Remuzzi G
Nat Rev Nephrol; 2016 Apr; 12(4):241-53. PubMed ID: 26853275
[TBL] [Abstract][Full Text] [Related]
11. Multipotent mesenchymal stromal cells in kidney transplant recipients: The next big thing?
Sergeant E; Buysse M; Devos T; Sprangers B
Blood Rev; 2021 Jan; 45():100718. PubMed ID: 32507576
[TBL] [Abstract][Full Text] [Related]
12. High-throughput RNA-sequencing identifies mesenchymal stem cell-induced immunological signature in a rat model of corneal allograft rejection.
Lu X; Chu C; Liu X; Gao Y; Wu M; Guo F; Li Y; Geng C; Huang Y; Zhang Y; Zhao S
PLoS One; 2019; 14(9):e0222515. PubMed ID: 31545822
[TBL] [Abstract][Full Text] [Related]
13. Transplantation of Kidneys From Hepatitis C Virus-Infected Donors to Hepatitis C Virus-Negative Recipients: One-Year Kidney Allograft Outcomes.
Molnar MZ; Azhar A; Tsujita M; Talwar M; Balaraman V; Bhalla A; Podila PSB; Kothadia J; Agbim UA; Maliakkal B; Satapathy SK; Kovesdy CP; Nair S; Eason JD
Am J Kidney Dis; 2021 May; 77(5):739-747.e1. PubMed ID: 33333148
[TBL] [Abstract][Full Text] [Related]
14. [Clinical study of mesenchymal stem cells from third-party donors in the treatment of refractory late onset hemorrhagic cystitis after allogeneic hematopoietic stem cell transplanation].
Zhao K; Huang F; Chen XY; Chang Y; Xu N; Shi PC; Liu H; Sun J; Xiang P; Liu QF; Fan ZP
Zhonghua Xue Ye Xue Za Zhi; 2022 Jun; 43(6):488-493. PubMed ID: 35968592
[No Abstract] [Full Text] [Related]
15. Safety and tolerability of bone marrow-derived mesenchymal stem cells in lupus animal models and a phase I clinical trial in humans.
Chun S; Choi CB; Kim MS; Nam JY; Lee TY; Lee YT; Kim S; Han SB; Bae SC
Lupus; 2022 Sep; 31(10):1245-1253. PubMed ID: 35802867
[TBL] [Abstract][Full Text] [Related]
16. Immunomodulation effects of mesenchymal stromal cells on acute graft-versus-host disease after hematopoietic stem cell transplantation.
Zhao K; Lou R; Huang F; Peng Y; Jiang Z; Huang K; Wu X; Zhang Y; Fan Z; Zhou H; Liu C; Xiao Y; Sun J; Li Y; Xiang P; Liu Q
Biol Blood Marrow Transplant; 2015 Jan; 21(1):97-104. PubMed ID: 25300866
[TBL] [Abstract][Full Text] [Related]
17. Autologous bone marrow-derived mesenchymal stem cells for interstitial fibrosis and tubular atrophy: a pilot study.
Zhang L; Lai X; Guo Y; Ma J; Fang J; Li G; Xu L; Yin W; Chen Z
Ren Fail; 2021 Dec; 43(1):1266-1275. PubMed ID: 34493167
[TBL] [Abstract][Full Text] [Related]
18. Co-transplantation of autologous MSCs delays islet allograft rejection and generates a local immunoprivileged site.
Ben Nasr M; Vergani A; Avruch J; Liu L; Kefaloyianni E; D'Addio F; Tezza S; Corradi D; Bassi R; Valderrama-Vasquez A; Usuelli V; Kim J; Azzi J; El Essawy B; Markmann J; Abdi R; Fiorina P
Acta Diabetol; 2015 Oct; 52(5):917-27. PubMed ID: 25808641
[TBL] [Abstract][Full Text] [Related]
19. Preformed donor-specific antibodies and risk of antibody-mediated rejection in repeat renal transplantation.
Tsapepas DS; Vasilescu R; Tanriover B; Coppleson Y; Rekhtman Y; Hardy MA; Dube G; Crew RJ; Ratner LE; Cohen DJ; Mohan S
Transplantation; 2014 Mar; 97(6):642-7. PubMed ID: 24637863
[TBL] [Abstract][Full Text] [Related]
20. Donor-derived mesenchymal stem cells combined with low-dose tacrolimus prevent acute rejection after renal transplantation: a clinical pilot study.
Peng Y; Ke M; Xu L; Liu L; Chen X; Xia W; Li X; Chen Z; Ma J; Liao D; Li G; Fang J; Pan G; Xiang AP
Transplantation; 2013 Jan; 95(1):161-8. PubMed ID: 23263506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
